Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 03, 2022 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors

PHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
September 26, 2022 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
September 06, 2022 07:00 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
August 25, 2022 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection

– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA – – First cell product candidate engineered with six precision...
August 11, 2022 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

- Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial in relapsed/refractory lymphoma is on track to commence in the second half...
June 24, 2022 16:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Announces Its Addition to the Russell Microcap® Index

PHILADELPHIA, June 24, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
June 21, 2022 16:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium

PHILADELPHIA, June 21, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
June 06, 2022 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022

PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
May 16, 2022 07:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence in the second half of 2022 following IND submission in mid 2022- - Ended first quarter 2022 with cash, cash...
May 03, 2022 16:30 ET | Source: Century Therapeutics, Inc.

Century Therapeutics to Present at Upcoming Investor Conferences

PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...